Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. has 1 licensing announcement in this dataset, dated 2021-06-01.
- Country / operating region
- Japan
- Ticker
- 4151.T
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.kyowakirin.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| KHK4083 / rocatinlimab | OX40 | antibody | Phase 3-ready | 2021-06-01 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| KHK4083 / rocatinlimab | All ongoing trials discontinued (2026-03-03) | — | 查無 | 查無 | 2026-03-03 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2021-06-01 | Amgen | KHK4083 / rocatinlimab | USD 400m | 查無 | ≤ USD 850m | 查無 | Historical agreement. All ongoing rocatinlimab clinical trials were discontinued on 2026-03-03. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Amgen | Worldwide excluding Japan; US co-promotion and selected opt-in rights | Royalty payments on future global sales; rate not disclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無